bcl6 sc 858 Search Results


bcl6 sc 858  (Santa Cruz Biotechnology)
94
Santa Cruz Biotechnology bcl6 sc 858
Figure 1 STAT5 activation is associated with repression of <t>BCL6.</t> (a) BCL1 cells were treated with IL-2 for 15 min, and analysed by immunoblot for phosphorylated STAT5. Total STAT5 was used as a loading control. (b) BCL1 cells were untreated or treated with IL-2 for 2 h, and RNA was analysed by q real-time PCR (qPCR) for BCL6 and CIS expression normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (c) Starved NKL cells were untreated or stimulated with IL-2 for 15 min, and analysed by immunoblot for phosphorylated STAT5 and STAT5a. (d) Starved NKL cells were untreated or stimulated with IL-2 for 2 h, after which mRNA was analysed by qPCR for BCL6 and CIS expression normalized to b-actin as an invariant control. (e) Starved NKL cells were untreated or stimulated with IL-2 and analysed by immunoblot for BCL6 protein expression. Total STAT5 was used as a loading control. (f) Starved 32D cells were untreated or stimulated with IL-3 for 2 h, and RNA was analysed by qPCR as in (b). (g) K562 cells were untreated or treated with 1 mM STI-571 for 30 min. STAT5a and STAT5b were immunoprecipitated separately and analysed by immunoblot with the indicated antibodies. (h) K562 cells were untreated or treated with STI-571 for 2 h, and RNA was analysed by qPCR as in (d). (i) Starved Ba/f3-tet-1*6 cells were untreated or treated with dox, and RNA was analysed by qPCR as in (b).
Bcl6 Sc 858, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcl6+sc+858/Bcl-6/pm16819511-200-39-42
Average 94 stars, based on 1 article reviews
bcl6 sc 858 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
rabbit polyclonal antibodies to bcl6  (Bio-Rad)
93
Bio-Rad rabbit polyclonal antibodies to bcl6
Figure 1 STAT5 activation is associated with repression of <t>BCL6.</t> (a) BCL1 cells were treated with IL-2 for 15 min, and analysed by immunoblot for phosphorylated STAT5. Total STAT5 was used as a loading control. (b) BCL1 cells were untreated or treated with IL-2 for 2 h, and RNA was analysed by q real-time PCR (qPCR) for BCL6 and CIS expression normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (c) Starved NKL cells were untreated or stimulated with IL-2 for 15 min, and analysed by immunoblot for phosphorylated STAT5 and STAT5a. (d) Starved NKL cells were untreated or stimulated with IL-2 for 2 h, after which mRNA was analysed by qPCR for BCL6 and CIS expression normalized to b-actin as an invariant control. (e) Starved NKL cells were untreated or stimulated with IL-2 and analysed by immunoblot for BCL6 protein expression. Total STAT5 was used as a loading control. (f) Starved 32D cells were untreated or stimulated with IL-3 for 2 h, and RNA was analysed by qPCR as in (b). (g) K562 cells were untreated or treated with 1 mM STI-571 for 30 min. STAT5a and STAT5b were immunoprecipitated separately and analysed by immunoblot with the indicated antibodies. (h) K562 cells were untreated or treated with STI-571 for 2 h, and RNA was analysed by qPCR as in (d). (i) Starved Ba/f3-tet-1*6 cells were untreated or treated with dox, and RNA was analysed by qPCR as in (b).
Rabbit Polyclonal Antibodies To Bcl6, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcl6+sc+858/Lyphochek+Tumor+Marker+Plus+Control/pmc01863460-183-32-12
Average 93 stars, based on 1 article reviews
rabbit polyclonal antibodies to bcl6 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
anti bcl6 antibody  (Santa Cruz Biotechnology)
94
Santa Cruz Biotechnology anti bcl6 antibody
Figure 1 STAT5 activation is associated with repression of <t>BCL6.</t> (a) BCL1 cells were treated with IL-2 for 15 min, and analysed by immunoblot for phosphorylated STAT5. Total STAT5 was used as a loading control. (b) BCL1 cells were untreated or treated with IL-2 for 2 h, and RNA was analysed by q real-time PCR (qPCR) for BCL6 and CIS expression normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (c) Starved NKL cells were untreated or stimulated with IL-2 for 15 min, and analysed by immunoblot for phosphorylated STAT5 and STAT5a. (d) Starved NKL cells were untreated or stimulated with IL-2 for 2 h, after which mRNA was analysed by qPCR for BCL6 and CIS expression normalized to b-actin as an invariant control. (e) Starved NKL cells were untreated or stimulated with IL-2 and analysed by immunoblot for BCL6 protein expression. Total STAT5 was used as a loading control. (f) Starved 32D cells were untreated or stimulated with IL-3 for 2 h, and RNA was analysed by qPCR as in (b). (g) K562 cells were untreated or treated with 1 mM STI-571 for 30 min. STAT5a and STAT5b were immunoprecipitated separately and analysed by immunoblot with the indicated antibodies. (h) K562 cells were untreated or treated with STI-571 for 2 h, and RNA was analysed by qPCR as in (d). (i) Starved Ba/f3-tet-1*6 cells were untreated or treated with dox, and RNA was analysed by qPCR as in (b).
Anti Bcl6 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcl6+sc+858/Bcl-6+Antibody/pmc05715737-265-6-9
Average 94 stars, based on 1 article reviews
anti bcl6 antibody - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

Image Search Results


Figure 1 STAT5 activation is associated with repression of BCL6. (a) BCL1 cells were treated with IL-2 for 15 min, and analysed by immunoblot for phosphorylated STAT5. Total STAT5 was used as a loading control. (b) BCL1 cells were untreated or treated with IL-2 for 2 h, and RNA was analysed by q real-time PCR (qPCR) for BCL6 and CIS expression normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (c) Starved NKL cells were untreated or stimulated with IL-2 for 15 min, and analysed by immunoblot for phosphorylated STAT5 and STAT5a. (d) Starved NKL cells were untreated or stimulated with IL-2 for 2 h, after which mRNA was analysed by qPCR for BCL6 and CIS expression normalized to b-actin as an invariant control. (e) Starved NKL cells were untreated or stimulated with IL-2 and analysed by immunoblot for BCL6 protein expression. Total STAT5 was used as a loading control. (f) Starved 32D cells were untreated or stimulated with IL-3 for 2 h, and RNA was analysed by qPCR as in (b). (g) K562 cells were untreated or treated with 1 mM STI-571 for 30 min. STAT5a and STAT5b were immunoprecipitated separately and analysed by immunoblot with the indicated antibodies. (h) K562 cells were untreated or treated with STI-571 for 2 h, and RNA was analysed by qPCR as in (d). (i) Starved Ba/f3-tet-1*6 cells were untreated or treated with dox, and RNA was analysed by qPCR as in (b).

Journal: Oncogene

Article Title: STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas.

doi: 10.1038/sj.onc.1209775

Figure Lengend Snippet: Figure 1 STAT5 activation is associated with repression of BCL6. (a) BCL1 cells were treated with IL-2 for 15 min, and analysed by immunoblot for phosphorylated STAT5. Total STAT5 was used as a loading control. (b) BCL1 cells were untreated or treated with IL-2 for 2 h, and RNA was analysed by q real-time PCR (qPCR) for BCL6 and CIS expression normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (c) Starved NKL cells were untreated or stimulated with IL-2 for 15 min, and analysed by immunoblot for phosphorylated STAT5 and STAT5a. (d) Starved NKL cells were untreated or stimulated with IL-2 for 2 h, after which mRNA was analysed by qPCR for BCL6 and CIS expression normalized to b-actin as an invariant control. (e) Starved NKL cells were untreated or stimulated with IL-2 and analysed by immunoblot for BCL6 protein expression. Total STAT5 was used as a loading control. (f) Starved 32D cells were untreated or stimulated with IL-3 for 2 h, and RNA was analysed by qPCR as in (b). (g) K562 cells were untreated or treated with 1 mM STI-571 for 30 min. STAT5a and STAT5b were immunoprecipitated separately and analysed by immunoblot with the indicated antibodies. (h) K562 cells were untreated or treated with STI-571 for 2 h, and RNA was analysed by qPCR as in (d). (i) Starved Ba/f3-tet-1*6 cells were untreated or treated with dox, and RNA was analysed by qPCR as in (b).

Article Snippet: Antibodies used include phospho-specific STAT5 (9351), phospho-p44/42 MAPK (9101), p44/42 MAPK (9102), phospho-Akt (9271) and Akt (9272) from Cell Signaling; STAT5b (71-2500; Zymed, South San Francisco, CA, USA); and total STAT5 (sc-835), STAT5a (sc-1081), STAT1 (sc-346), STAT3 (sc-482) and BCL6 (sc-858) from Santa Cruz Biotechnology (Santa Cruz, CA, USA). mRNA expression RNA was harvested using an RNeasy Mini Kit from Qiagen (Valencia, CA, USA). cDNA was generated using the SuperScript First Stand Synthesis kit (Invitrogen, Carlsbad, CA, USA) or the TaqMan Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA).

Techniques: Activation Assay, Western Blot, Control, Real-time Polymerase Chain Reaction, Expressing, Immunoprecipitation

Figure 2 (a) Inhibition of BCL6 by STAT5 relieves the repression on BCL6 target genes. Starved NKL cells were untreated or stimulated with IL-2 for 24 h, and RNA was analysed by qPCR normalized to GAPDH as an invariant control. (b) Inhibition of STAT5 activation results in BCL6 expression and repression of BCL6 target genes. K562 cells were untreated or treated with STI-571 for 24 h, and RNA was analysed by qPCR as in (a).

Journal: Oncogene

Article Title: STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas.

doi: 10.1038/sj.onc.1209775

Figure Lengend Snippet: Figure 2 (a) Inhibition of BCL6 by STAT5 relieves the repression on BCL6 target genes. Starved NKL cells were untreated or stimulated with IL-2 for 24 h, and RNA was analysed by qPCR normalized to GAPDH as an invariant control. (b) Inhibition of STAT5 activation results in BCL6 expression and repression of BCL6 target genes. K562 cells were untreated or treated with STI-571 for 24 h, and RNA was analysed by qPCR as in (a).

Article Snippet: Antibodies used include phospho-specific STAT5 (9351), phospho-p44/42 MAPK (9101), p44/42 MAPK (9102), phospho-Akt (9271) and Akt (9272) from Cell Signaling; STAT5b (71-2500; Zymed, South San Francisco, CA, USA); and total STAT5 (sc-835), STAT5a (sc-1081), STAT1 (sc-346), STAT3 (sc-482) and BCL6 (sc-858) from Santa Cruz Biotechnology (Santa Cruz, CA, USA). mRNA expression RNA was harvested using an RNeasy Mini Kit from Qiagen (Valencia, CA, USA). cDNA was generated using the SuperScript First Stand Synthesis kit (Invitrogen, Carlsbad, CA, USA) or the TaqMan Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA).

Techniques: Inhibition, Control, Activation Assay, Expressing

Figure 3 Identification of potential STAT5-binding sites in the BCL6 gene. (a) A schematic representation of the BCL6 gene highlighting the different variant (V) untranslated exons and relative locations of region A and region B. The sequences of region A ( þ 8029 to þ 8130) (b) and region B ( þ 441 to þ 544) (c) of the BCL6 gene are shown with the STAT consensus sites underlined. Sequence numbers are in reference to the þ 1 nucleotide identified by Ohashi et al. (1995). (d) Quantitation of homology as percent identity of human BCL6 to mouse and rat BCL6 in the first exon and intron of BCL6 using the Multi-VISTA browser.

Journal: Oncogene

Article Title: STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas.

doi: 10.1038/sj.onc.1209775

Figure Lengend Snippet: Figure 3 Identification of potential STAT5-binding sites in the BCL6 gene. (a) A schematic representation of the BCL6 gene highlighting the different variant (V) untranslated exons and relative locations of region A and region B. The sequences of region A ( þ 8029 to þ 8130) (b) and region B ( þ 441 to þ 544) (c) of the BCL6 gene are shown with the STAT consensus sites underlined. Sequence numbers are in reference to the þ 1 nucleotide identified by Ohashi et al. (1995). (d) Quantitation of homology as percent identity of human BCL6 to mouse and rat BCL6 in the first exon and intron of BCL6 using the Multi-VISTA browser.

Article Snippet: Antibodies used include phospho-specific STAT5 (9351), phospho-p44/42 MAPK (9101), p44/42 MAPK (9102), phospho-Akt (9271) and Akt (9272) from Cell Signaling; STAT5b (71-2500; Zymed, South San Francisco, CA, USA); and total STAT5 (sc-835), STAT5a (sc-1081), STAT1 (sc-346), STAT3 (sc-482) and BCL6 (sc-858) from Santa Cruz Biotechnology (Santa Cruz, CA, USA). mRNA expression RNA was harvested using an RNeasy Mini Kit from Qiagen (Valencia, CA, USA). cDNA was generated using the SuperScript First Stand Synthesis kit (Invitrogen, Carlsbad, CA, USA) or the TaqMan Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA).

Techniques: Binding Assay, Variant Assay, Sequencing, Quantitation Assay

Figure 4 Region B of the BCL6 gene is STAT5 responsive. 293 cells were transfected with A-Luc or B-Luc (a) or TBR-Luc (b), and STAT5a1*6 or vector control, and analysed for luciferase activity after 24 h.

Journal: Oncogene

Article Title: STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas.

doi: 10.1038/sj.onc.1209775

Figure Lengend Snippet: Figure 4 Region B of the BCL6 gene is STAT5 responsive. 293 cells were transfected with A-Luc or B-Luc (a) or TBR-Luc (b), and STAT5a1*6 or vector control, and analysed for luciferase activity after 24 h.

Article Snippet: Antibodies used include phospho-specific STAT5 (9351), phospho-p44/42 MAPK (9101), p44/42 MAPK (9102), phospho-Akt (9271) and Akt (9272) from Cell Signaling; STAT5b (71-2500; Zymed, South San Francisco, CA, USA); and total STAT5 (sc-835), STAT5a (sc-1081), STAT1 (sc-346), STAT3 (sc-482) and BCL6 (sc-858) from Santa Cruz Biotechnology (Santa Cruz, CA, USA). mRNA expression RNA was harvested using an RNeasy Mini Kit from Qiagen (Valencia, CA, USA). cDNA was generated using the SuperScript First Stand Synthesis kit (Invitrogen, Carlsbad, CA, USA) or the TaqMan Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA).

Techniques: Transfection, Plasmid Preparation, Control, Luciferase, Activity Assay